Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 May;71(5):957–962. doi: 10.1038/bjc.1995.185

Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.

D H Horber 1, H Schott 1, R A Schwendener 1
PMCID: PMC2033768  PMID: 7734320

Abstract

The in vitro deamination, cytotoxicity, cellular drug uptake, distribution and cellular pharmacology in HL-60 cells of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC), a lipophilic derivative of arabinofuranosylcytosine (ara-C), were studied. Compared with ara-C, NHAC in liposomal formulations was highly resistant to deamination, resulting in levels of formation of arabinofuranosyluracil 42 and ten times lower in plasma and liver microsomes respectively. The cytotoxicity of NHAC was independent of both the nucleoside transporter mechanism and the deoxycytidine (dCyd) kinase activity as demonstrated by co-incubating NHAC with dipyridamole and/or dCyd. In ara C-resistant HL-60 cells NHAC was still cytotoxic, requiring drug concentration only 1.6 times higher than sensitive cells. Uptake of NHAC was six times higher and was not inhibited by dipyridamole. The pharmacokinetics of NHAC revealed that its intracellular half-life is 4.8 times longer than that of ara-C. Ara-CTP formation and incorporation into DNA was up to 25-50 times lower than that of ara-C and contributed only marginally to the cytotoxic effects of NHAC. These results indicate that, because of the significantly increased stability, the transporter-independent uptake and the dCyd-kinase-independent cytotoxicity, NHAC might be active in ara-C-resistant cells.

Full text

PDF
957

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoshima M., Tsukagoshi S., Sakurai Y., Oh-ishi J., Ishida T. Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine. Cancer Res. 1976 Aug;36(8):2726–2732. [PubMed] [Google Scholar]
  2. Bhalla K., Nayak R., Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res. 1984 Nov;44(11):5029–5037. [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. CHU M. Y., FISCHER G. A. COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE. Biochem Pharmacol. 1965 Mar;14:333–341. doi: 10.1016/0006-2952(65)90198-x. [DOI] [PubMed] [Google Scholar]
  5. Coleman C. N., Stoller R. G., Drake J. C., Chabner B. A. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood. 1975 Nov;46(5):791–803. [PubMed] [Google Scholar]
  6. Driscoll J. S., Marquez V. E., Plowman J., Liu P. S., Kelley J. A., Barchi J. J., Jr Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem. 1991 Nov;34(11):3280–3284. doi: 10.1021/jm00115a017. [DOI] [PubMed] [Google Scholar]
  7. Frei E., 3rd, Bickers J. N., Hewlett J. S., Lane M., Leary W. V., Talley R. W. Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res. 1969 Jul;29(7):1325–1332. [PubMed] [Google Scholar]
  8. Furth J. J., Cohen S. S. Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine. Cancer Res. 1968 Oct;28(10):2061–2067. [PubMed] [Google Scholar]
  9. Ho D. H., Frei E., 3rd Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther. 1971 Nov-Dec;12(6):944–954. doi: 10.1002/cpt1971126944. [DOI] [PubMed] [Google Scholar]
  10. Kanai T., Ichino M. Pyrimidine nucleosides. 6. Syntheses and anticancer activities of N4-substituted 2,2'-anhydronucleosides. J Med Chem. 1974 Oct;17(10):1076–1078. doi: 10.1021/jm00256a010. [DOI] [PubMed] [Google Scholar]
  11. Kataoka T., Sakurai Y. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine. Recent Results Cancer Res. 1980;70:147–151. doi: 10.1007/978-3-642-81392-4_15. [DOI] [PubMed] [Google Scholar]
  12. Keating M. J., McCredie K. B., Bodey G. P., Smith T. L., Gehan E., Freireich E. J. Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA. 1982 Nov 19;248(19):2481–2486. [PubMed] [Google Scholar]
  13. King M. E., Naporn A., Young B., Howell S. B. Modulation of cytarabine uptake and toxicity by dipyridamole. Cancer Treat Rep. 1984 Feb;68(2):361–366. [PubMed] [Google Scholar]
  14. Kolla S. S., Studzinski G. P. Constitutive DNA binding of the low mobility forms of the AP-1 and SP-1 transcription factors in HL60 cells resistant to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1994 Mar 15;54(6):1418–1421. [PubMed] [Google Scholar]
  15. Kreis W., Budman D. R., Chan K., Allen S. L., Schulman P., Lichtman S., Weiselberg L., Schuster M., Freeman J., Akerman S. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. Leukemia. 1991 Nov;5(11):991–998. [PubMed] [Google Scholar]
  16. Kufe D., Spriggs D., Egan E. M., Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood. 1984 Jul;64(1):54–58. [PubMed] [Google Scholar]
  17. Major P. P., Egan E. M., Beardsley G. P., Minden M. D., Kufe D. W. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A. 1981 May;78(5):3235–3239. doi: 10.1073/pnas.78.5.3235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Momparler R. L. A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1974 Aug;34(8):1775–1787. [PubMed] [Google Scholar]
  19. Momparler R. L., Onetto-Pothier N., Bouffard D. Y., Momparler L. F. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. Cancer Chemother Pharmacol. 1990;27(2):141–146. doi: 10.1007/BF00689099. [DOI] [PubMed] [Google Scholar]
  20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  21. Plagemann P. G., Marz R., Wohlhueter R. M. Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res. 1978 Apr;38(4):978–989. [PubMed] [Google Scholar]
  22. Plunkett W., Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 1993 Feb;20(1):50–63. [PubMed] [Google Scholar]
  23. Rosowsky A., Kim S. H., Ross J., Wick M. M. Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs. J Med Chem. 1982 Feb;25(2):171–178. doi: 10.1021/jm00344a016. [DOI] [PubMed] [Google Scholar]
  24. Rubas W., Supersaxo A., Weder H. G., Hartmann H. R., Hengartner H., Schott H., Schwendener R. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer. 1986 Jan 15;37(1):149–154. doi: 10.1002/ijc.2910370123. [DOI] [PubMed] [Google Scholar]
  25. Schwendener R. A., Schott H. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine. Int J Cancer. 1992 May 28;51(3):466–469. doi: 10.1002/ijc.2910510321. [DOI] [PubMed] [Google Scholar]
  26. Spriggs D., Robbins G., Ohno Y., Kufe D. Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res. 1987 Dec 15;47(24 Pt 1):6532–6536. [PubMed] [Google Scholar]
  27. Steuart C. D., Burke P. J. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol. 1971 Sep 22;233(38):109–110. doi: 10.1038/newbio233109a0. [DOI] [PubMed] [Google Scholar]
  28. Tattersall M. H., Ganeshaguru K., Hoffbrand A. V. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br J Haematol. 1974 May;27(1):39–46. doi: 10.1111/j.1365-2141.1974.tb06772.x. [DOI] [PubMed] [Google Scholar]
  29. Ueda T., Nakamura T., Kagawa D., Yamamoto K., Uchida M., Sasada M., Uchino H. Intracellular distribution of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in blood cells. Gan. 1983 Jun;74(3):445–451. [PubMed] [Google Scholar]
  30. Wempen I., Miller N., Falco E. A., Fox J. J. Nucleosides. XLVII. Synthesis of some N4-substituted derivarives of 1-beta-D-arabinofuranosylcytosine and -5-fluorocytosine. J Med Chem. 1968 Jan;11(1):144–148. doi: 10.1021/jm00307a034. [DOI] [PubMed] [Google Scholar]
  31. Wiley J. S., Jones S. P., Sawyer W. H., Paterson A. R. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest. 1982 Feb;69(2):479–489. doi: 10.1172/JCI110472. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES